KEY WORD 1998-2000 血液

出版社： 先端医学社
著者：
発行日： 1998-08-30
分野： 臨床医学：内科  >  血液
ISBN： 9784915892639
電子書籍版： 1998-08-30 （第1版第1刷）
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,475 円(税込)

購入する

商品紹介

進展著しい血液理解に必須の112項目を精選し、見開き2頁にわたって解説。
最先端の情報をコンパクトに整理できる好評KEY WORDシリーズ。進展著しい医学各領域における基礎から臨床の話題まで最新の動向をいち早く理解するために必要なキーワードを厳選。各分野での第一人者が見開き2頁にわたり平易に解説。トランスレーショナル・リサーチの理解の一助として医師、研究者のみならず、広く医療にかかわる方々の、より正確な知識の把握と整理のための座右の書。

目次

  • 表紙
  • 序
  • 執筆者一覧
  • 略語一覧
  • 目次
  • あ行 悪性リンパ腫のREAL分類
  • 悪性リンパ腫の国際予後指数
  • アポトーシス
  • アポトーシス抑制遺伝子
  • アミロイドーシスと4'-ヨード-4'デオキシドキソルビシン
  • アンチセンス療法
  • イダルビシン
  • 一酸化窒素合成酵素
  • Interferon regulatory factor-1
  • インターロイキン-3
  • インターロイキン-5
  • インターロイキン-6
  • インターロイキン-11
  • ウイルムス腫瘍遺伝子
  • ウロキナーゼ型プラスミノゲンアクチベーター受容体
  • SCL/TAL-1遺伝子
  • flt3/flk2リガンド
  • mdr遺伝子
  • エリスロポエチン受容体異常
  • エリスロポエチンの臨床応用
  • ob受容体アイソフォームとレプチン
  • オンコスタチンM
  • か行 外因系凝固インヒビター
  • GATA転写因子群
  • 活性化プロテイン抵抗性
  • 顆粒球コロニー刺激因子受容体異常
  • 顆粒リンパ球増多症
  • 幹細胞因子
  • 急性白血病の化学療法
  • Coombs陰性自己免疫性溶血性貧血
  • クラドリビン
  • グルタチオン転移酵素θ1遺伝子
  • 血液疾患とクローン性
  • 血管内皮細胞プロテインC受容体
  • 血管内皮増殖因子
  • 血管内皮由来弛緩因子
  • 血球貧食症候群
  • 血小板活性化因子
  • 血小板由来成長因子
  • 血栓血小板減少性紫斑病
  • ゲニスタイン
  • 好酸球増加症候群
  • 抗GIIb/IIIa阻害薬
  • 抗リン脂質抗体症候群
  • 骨髄移植
  • さ行 再生不良性貧血とHLA
  • 再生不良性貧血の免疫抑制療法
  • 臍帯血幹細胞移植
  • サイトカイン受容体
  • Signal transducer and activator of transcription
  • シクロオキシゲナーゼ
  • CD34
  • 若年型慢性骨髄性白血病
  • Jak2阻害薬
  • 除鉄薬
  • ずり応力惹起血小板凝集
  • 成人T細胞白血病・悪性リンパ腫
  • 先天性溶血性貧血の遺伝子異常
  • 栓友病
  • 造血因子のシグナル伝達
  • 造血幹細胞の純化
  • 造血幹細胞の増幅
  • 組織因子
  • た行 耐性克服薬
  • 多発性骨髄腫の治療
  • 治療関連白血病
  • 低分子ヘパリン
  • 鉄芽球性貧血の遺伝子異常
  • de novo AML with trilineage myelodysplasia
  • テロメアとテロメラーゼ
  • Transforming growth factor-β
  • トランスリン遺伝子
  • トロンビン受容体
  • トロンボキサンA2受容体
  • トロンボポエチン
  • トロンボモジュリン
  • な行 Nuclear factor erythroid 2
  • NeoPlastic angioendotheliosis
  • は行 白血病抑制因子
  • 播種性血管内凝固症候群
  • BCL-6遺伝子
  • PIG-A遺伝子
  • p15,p16遺伝子
  • P-セレクチン
  • 肥満細胞増加症とc-kitの突然変異
  • 鼻腔リンパ腫
  • ヒルジン
  • ファンコニー貧血
  • フォン ウィルブランド因子
  • プラスミノゲンアクチベーター
  • プラスミノゲンアクチベーターインヒビター
  • フルダラビン
  • プロスタグランジン合成酵素
  • プロテインCインヒビター
  • プロトロンビン・フラグメント1+2
  • 分化誘導療法
  • ヘアリー細胞白血病
  • ヘパリン起因性血小板減少症
  • HELLP症候群
  • ホスホリパーゼ
  • ホメオボックス遺伝子
  • ま行 マクロファージコロニー刺激因子
  • 末梢血幹細胞移植
  • MALTomaとHelicobacter pylori感染
  • 慢性骨髄性白血病のインターフェロン療法
  • マントル細胞リンパ腫
  • 末分化大細胞型リンパ腫
  • 眼由来増殖因子
  • モノソミー7症候群
  • や行 輸血後移植片対宿主病
  • ら行 ラミニン
  • レチノイン酸症候群
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

あ行 悪性リンパ腫のREAL分類

P.11 掲載の参考文献
1) Harris, N.L. et al.:A revised European American classification of lymphoid neoplasms:a proposal from the International Lympoma Study Group. Blood 84:1361-1392, 1994
 
P.13 掲載の参考文献
1) Shipp, M., Harrington, DP., Anderson, J.R. et al.:The International Non-Hodgkin's lymphoma prognostic factors project:a predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 329:987-994, 1993
 
2) Lopez-Guillermo, A., Monserrat, E., Bosch, F. et al.:Applicability of the international index for aggressive lymphoma to patients with low-grade lymphoma J. Clin. Oncol. 12:1343-1348, 1994
 
3) Harris, N.L., Jaffe, E.S., Stein, H. et al.:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
 
P.15 掲載の参考文献
1) 古川雄祐:分化とアポトーシス. 癌細胞の分化誘導とアポトーシス, 共立出版, 東京, 1995, pp.131-149
 
2) White, E.:Life, death, and the pursuit of apoptosis. Genes Dev. 10:1-15, 1996
PubMed
3) Takahashi, A. and Earnshaw, W.C.:ICE-related proteases in apoptosis. Curr. Opin. Genet. Dev. 6:50-55, 1996
PubMed
P.17 掲載の参考文献
1) Yang, E. and Korsmeyer, S.L.:Molecular thanatopsis:a discourse on the BCL2 family and cell death. Blood 88:386-401, 1996
 
2) Hannun, Y.A.:Apoptosis and the dillemma of cancer chemotherapy. Blood 89:1845-1853, 1997
 
3) Webb, A., Cunningham, D., Cotter, F. et al.:BCL-2 antisence therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-1141, 1997
 
P.19 掲載の参考文献
1) Barbieri, B., Giuliani, F.C., Bordoni, T. et al.:Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. Cancer Res. 47:4001-4006, 1987
PubMed
2) Merlini, G., Ascari, E., Amboldi, N. et al.:Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils:inhibition of amyloidogenesis. Proc. Natl. Acad. Sci. USA 92:2959-2963, 1995
PubMed
3) Gianni, L., Bellotti, V., Gianni, A.M. et al.:New drug therapy of amyloidoses:Resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood 86:855-861, 1995
PubMed
P.21 掲載の参考文献
1) Wagner, R.W. and Flanagan, W.M.:Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today 3:31-38, 1997
PubMed
2) Braun, S.E., Chen, K., Battiwalla, M. et al.:Gene therapy strategies for leukemia. Mol. Med. Today 3:39-46, 1997
PubMed
3) Tonkinson, J.L. and Stein, C.A.:Antisense oligonucleotides as clinical therapeutic agents. Cancer Invest. 14:54-65, 1996
PubMed
4) Plenet, F.:Animal models of antisense oligonucleotides:lessons for use in humans. Mol. Med. Today 2:250-257, 1996
 
P.23 掲載の参考文献
1) Ganzina, F., Pacciarini, M.A. and Pietro, N.:Idarubicin (4-demethory-daunorubicin). A preliminary overview of preclinical and clinical studies. Invest. New. Drugs. 4:85-105, 1986
PubMed
2) 小川一誠:新しい抗白血病剤-イダルビシン-. 医学のあゆみ17:967-970, 1995
 
3) 正岡徹, 小川一誠, 山田一正ほか:成人急性非リンパ性白血病 (ANLL) に対するIdarubicin+Cytarabine 療法とDaunorubicin+Cytarabine療法の後期第II相比較試験. 癌と化学療法20:1995-2005, 1993
 
P.25 掲載の参考文献
1) 戸田昇編:NO. 最新医学からのアプローチ, メジカルビュー社, 東京, 1995
 
2) Sessa, W.:The nitric oxide synthase family of protein. J. Vasc. Res. 31:131-143, 1994
 
3) Lowenstein, C., Dinerman, J. and Snyder, S.:Nitric oxide:a physiologic messnger. Ann. Intern. Med. 120:227-237, 1994
 
P.27 掲載の参考文献
1) Taniguchi, T. et al.:Regulation of the interferon system and cell growth by the IRF trans-cription factors. J. Cancer Res. Clin. Oncol. 121:516-520, 1995
 
P.29 掲載の参考文献
1) Ihle, J.N., Paersack, L. and Rebar, L:Regulation of T cell differentiation:in vitro induction of 20 α-hydroxysteroid dehydrogenase in splenic lymphocytes from athymic mice by a unique lymphokine. J. Immunol. 126:2184-2189, 1981
 
2) Ogawa, M.:Differentiation and proliferation of hematopoietic stem cells. Blood 81:2844-2853, 1993
PubMed
P.31 掲載の参考文献
1) Sanderson, C.J.:Interleukin-5, eosinophils, and disease. Blood 79:3101-3109, 1992
PubMed
2) Kopf, M., Brombacher, K., Hodgkin, P.D. et al.:IL-5-deficient mice have a developmental defect in CD5+B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4:15-24, 1996
 
3) Yoshida, T., Ikuta, K., Sugaya, H. et al.:Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5Rα-deficient mice. Immunity 4:483-494, 1996
 
P.33 掲載の参考文献
1) Kishimoto, T. et al.:Interleukin-6 and receptor. A paradigm for cytokines. Science 258:593-597, 1992
PubMed
2) 審良静男:転写因子によるIL-6発現調節. 治療学31:32-38, 1996
 
3) 田賀哲也:gp130を共有するサイトカイン群の受容体とシグナル伝達機構. 実験医学14:1372-1379, 1996
 
P.35 掲載の参考文献
1) Du, X.X. and Williams, D.A.:Interleukin-11:a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 83:2023-2030, 1994
PubMed
2) 寺村正尚:インターロイキン11 (IL-11). 臨床免疫 (suppl. 16):107-112, 1995
 
P.37 掲載の参考文献
1) Inoue, K., Ogawa, H., Yamagami, T. et al.:Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms Tumor Gene) expression levels. Blood 88:2267, 1996
PubMed
2) Tamaki, H., Ogawa, H., Inoue, K. et al.:Increased expression level of the wilms tumor gene (WT1) at relapse in acute leukemia. Blood 88:4396, 1996
 
3) Tenen, D.G., Hromas, R., Licht, J.D. et al.:Trascription factors, normal myeloid development, and leukemia. Blood 90:502, 1997
 
P.40 掲載の参考文献
1) Donφ, K., Behrenalt, N., Brunner, V. et al.:The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:189-203, 1994
 
2) Strickland, D.K., Kounnas, M.Z., Williams, S.E. et al.:LDL receptor-related protein (LRP):a multiligand receptor. Fibrinolysis 8:204-215, 1994
 
3) Blasi, F.:Urokinase and urokinase receptor:a paracrine / autocrine system regulating cell migration and invasiveness. BioEssays 15:105-111, 1993
PubMed
P.43 掲載の参考文献
1) Begley, C.G., Aplan, P.D., Denning, D.S. et al.:The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc. Natl. Acad. Sci. USA 86:10128-10132, 1989
 
2) Shimamoto, T., Ohyashiki, K., Ohyashiki, J.H. et al.:The expression pattern of erythrocyte/megakaryocyte-related transcription factors, GATA-1, GATA-2 and SCL, correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 86:3173-3180, 1955
 
3) Ohyashiki, K., Ohyashiki, J.H., Shimamoto, T. et al:Expression pattern of GATA family, stem cell leukemia gene, and EVI-1 in human leukemia and myelodysplastic syndrome. Leuk. Lymphoma 23:431-436, 1996
 
P.45 掲載の参考文献
1) Lyman, S.D., Brasel, K., Rousseau, A.-M. et al.:The flt3 ligand:a hematopoietic stem cell factor whose activities are distinct from steel factor. Stem Cells 12:99-110, 1994
PubMed
2) Lyman, S.D.:Biology of flt3 ligand and receptor. I. J. Hematol. 62:63-73, 1995
 
3) 岩間厚志, 須田年生:Flk2/Flk3のリガンドとその作用. 血液腫瘍科32:239-246, 1996
 
P.47 掲載の参考文献
1) Gottesman, M.M. and Pastan, I.:The Multidrug transporter, a Double-edged Sword. J. Biol. Chem. 263:12163-12166, 1988
 
2) Licht, T., Pastan , I., Gottesman, M.M. et al.:P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann. Hematol. 69:159-171, 1994
 
3) Hiroshi, S.:Multidrug Resistance in leukemia. Teikyo Med. J. 19:305-327, 1996
 
P.49 掲載の参考文献
1) 小松則夫:多血症とエリスロポエチンレセプター異常. Annual Review 血液1995, 高久史麿ほか編, 中外医学社, 東京, 1995, pp.62-68
 
2) 小松則夫:エリスロポエチン受容体の構造と機能. Annual Review 血液1996, 高久史麿ほか編, 中外医学社, 東京, 1996, pp.73-78
 
P.51 掲載の参考文献
1) 特集:エリスロポエチンの応用～新しい展開～. 日常診療と血液6:499-544, 1996
 
2) Ludwig,H., Sundal, E., Pecherstorfer, M. et al.:Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76:2319-2329, 1995
PubMed
P.54 掲載の参考文献
1) Lee, Gwo-Hwa., Proenca, R., Montez, J.M. et al.:Abnormal splicing of the leptin receptor in diabetic mice. Nature 379:632-635, 1996
 
2) Ghilardi, N., Ziegler, S., Wiestner, A. et al.:Defective STAT signaling by the leptin receptor in diabetic mice. Proc. Natl. Acad. Sci. USA 93:6231-6235, 1996
PubMed
3) 小川佳宏, 細田公則, 中尾一和:obese(ob) 遺伝子と diabetes(db) 遺伝子-新しいエネルギー代謝調節系の分子機構, 実験医学14:2236-2242, 1996
 
4) Cioffi, J.A, . Shafer, A.W., Zupancic, T.J. et al.:Novel B219/OB receptor isoforms:possible role of leptin in hematopoiesis and reproduction. Nat. Med. 2:585-589, 1996
PubMed
5) Bennett, B.D., Solar, G.P., Yuan, J.Q. et al.:A role for leptin and its cognate receptor in hematopoiesis. Curr. Biol. 6:1170-1180
 
6) Gainsford, T., Willson, T.A., Metcalf, D. et al.:Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. USA 93:14564-14568, 1996
PubMed
7) Mikhail, A.A., Beck, E.X., Shafer, A. et al.:Leptin stimulates fetal and adult erythroid and myeloid development. Blood 89:1507-1512, 1997
PubMed
8) Umemoto, Y., Tsuji, K., Yang, F. et al.:Leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells. Blood 90:3438-3443, 1997
PubMed
P.57 掲載の参考文献
1) Wallace, P.M., Macmaster, J.F., Rillema, J.R. et al.:In vivo properties of oncostatin M. Ann. NY Acad. Sci. 762:42-54, 1995
PubMed
2) 前川平:OSM (Oncostatin M) . サイトカインの基礎と臨床, 平嶋邦猛, 浅野茂隆, 朝長万左男編, メディカルレビュー社, 東京, 1996, pp.159-162
 

か行 外因系凝固インヒビター

P.59 掲載の参考文献
1) 加藤久雄:外因系凝固インヒビターTFPIの最近のトピックス. 血栓止血誌5:389-406, 1994
 
2) 加藤久雄, 円城寺慶一:Tissue Factor Pathway Inhibitor (TFPI). 動脈硬化23:511-517, 1996
 
3) 加藤久雄, 和田英夫, 久米田幸介:内皮細胞結合型外因系凝固インヒビター (TFPI) と高脂血症. 動脈硬化 24:461-467, 1997
 
P.61 掲載の参考文献
1) 峯岸直子, 山本雅之:赤血球分化と転写因子. Annual Review 血液1996, 高久史麿ほか編, 中外医学社, 東京, 1996, pp.52-65
 
2) 高橋智, 山本雅之:GATA遺伝子ファミリー. ジーンターゲティングファイル～'97. 実験医学増刊14:120-123, 1996
 
3) Shivdasani, R.A. and Orkin, S.H.:The transcriptional control of hematopoiesis. Blood 87:4025-4039, 1996
PubMed
P.63 掲載の参考文献
1) Bertina, R.M.:Laboratory diagnosis of resistance to activated protein C(APC-resistance). Thromb. Haemost. 78:478-482, 1997
PubMed
2) Dahlback, B.:Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb. Haemost. 78:483-488, 1997
PubMed
P.65 掲載の参考文献
1) Avalos, B.R.:Molecular analysis of the granulo cyte colony-stimulating factor receptor. Blood 88:761-777, 1996
 
2) 岡村精一, 下田和哉:G-CSFレセプターのシグナル伝達機構とその異常. Annual Review 血液1997, 中外医学社, 東京, 1997, pp.114-129
 
P.67 掲載の参考文献
1) Oshimi, K., Yamada, 0., Kaneko, T. et al.:Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders (Review). Leukemia 7:782-788, 1993
 
2) Oshimi, K.:Lymphoproliferative disorders of natural killer cells (Review). Int. J. Hematol. 163:279-290, 1996
 
P.69 掲載の参考文献
1) Witte, O.N.:Steel locus defines new multipotent growth factor. Cell 63:5-6, 1990
PubMed
2) Galli, S.J., Zsebo, K.M. and Geissler, E.N.:The kit ligand, stem cell factor. Adv. Immunol. 55:1-96, 1994
PubMed
3) Broudy, V.C.:Stem cell factor and hematopoiesis. Blood 90:1345-1364, 1997
PubMed
P.71 掲載の参考文献
1) 大野竜三:生存からみた急性白血病化学療法の進歩. 癌と化学療法22:431-436, 1995
 
2) 大野竜三:急性骨髄性白血病の治療指針. 血液・腫瘍科31 (suppl.1):47-51, 1995
 
3) 大野竜三:成人リンパ性白血病の治療指針. Annual Review 血液1996高久史麿ほか編, 中外医学社, 東京, 1996, pp.145-156
 
P.73 掲載の参考文献
1) Gilliland, B.C.:Coombs-negative immune hemolytic anemia. Semin. Hematol. 13:267-275, 1976
PubMed
2) Ramos, R.R., Curtis, B.R., Sadler, J.E. et al.:Refractory immune hemolytic anemia with a high thermal amplitude, low affinity IgG anti-Pra cold autoantibody. Auto-immunity 12:149-154, 1992
 
3) 梶井英治:Coombs陰性自己免疫性溶血性貧血の診断と治療. Annual Review 血液1997, 高久史麿ほか編, 中外医学社, 東京, 1997, pp.73-78
 
P.75 掲載の参考文献
1) Saven. A. and Piro, L.:Newer purine analogues for the treatment of hairy-cell leukemia. N. Engl. J. Med. 330:691-697, 1994
PubMed
2) Tobinai, K., Ogura, M., Hotta, T. et al.:Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Jpn. J. Clin. Oncol. 27:146-153, 1997
PubMed
3) Carson, D.A., Wasson, D.B., Lakow, E. et al.:Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc. Natl. Acad. Sci. USA 79:3848-3852, 1982
PubMed
P.77 掲載の参考文献
1) Nelson, H.H., Wiencke. J., Christian, D.C. et al.:Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 16:1243-1245, 1993
 
2) Chen, H., Sandler, D.P., Taylor, J.A. et al.:Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347:295-297, 1996
PubMed
3) Wiencke, J.K., Pemble, S., Ketterer, B. et al.:Gene deletion of glutathione S-transferase O:Correlation with induced genetic damage and potential role in endogeneous mutagenesis. Cancer Epidemiol. Biomarkers Prev. 4:253-259, 1995
 
P.79 掲載の参考文献
1) Allen, R.C., Zoghbi, H.Y., Moseley, A.B. et al.:Methylation of Hpa II and Hha I sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am. J. Hum. Genet. 52:1229-1239, 1992
 
2) Young, N.S.:The problem of clonality in aplastic anemia:Dr Dameshek's riddle, restated. Blood 79:1385-1392, 1992
PubMed
3) Busque, L. and Gilliland, D. G.:Clonal evolution in acute myeloid leikemia. Blood 82:337-342, 1993
 
4) Soenen, V., Fenaux, P., Flactif, M. et al.:Combined immunophenotyping and in situ hybridization (FICTION):a rapid method to study cell lineage in volvement in myelodysplastic syndromes. Br. J. Haematol. 90:701-706, 1995
 
P.81 掲載の参考文献
1) Fukudome, K. and Esmon, C.T.:Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J. Biol. Chem. 269:26486-26491,1994
PubMed
2) 福留健司:プロテインCレセプター. Annual Review 血液 1997, 中外医学社, 東京, 1997, pp.243-251
 
3) Stearns-Kurosawa, D.J., Kurosawa, S. et al.:The endothelial cell protein C receptor augments protein C activation by the thrombin-throm-bomodulin complex. Proc. Natl. Acad. Sci. USA 93:10212-10216,1996
 
4) Regan, L.M., Stearns-Kurosawa, D.J. et al.:The endothelial protein C receptor:inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J. Biol. Chem. 271:17499-17503,1996
 
5) Kurosawa, S., Stearns-Kurosawa, D.J. et al.:Identification of functional endothelial protein C receptor in human plasma. J. Clin. Invest. 100:411-418, 1997
PubMed
P.83 掲載の参考文献
1) Ferrara, N., Houck, K., Jakeman, L. et al.:Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13:18-32, 1992
PubMed
2) Shibuya, M.:Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 67:281-316, 1995
PubMed
3) Mustonen, T. and Alitalo, K.:Enodthelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. 129:895-898, 1995
 
P.85 掲載の参考文献
1) Billiar, T.:Nitric oxide. Novel biology with clinical relevance. Ann. Surg. 221:339-349, 1995
PubMed
2) Loscalzo, J. and Welch, G.:Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis. 38:87-104, 1995
PubMed
3) Moilanen, E. and Vapaatalo, H.:Nitric oxide in inflammation and immune response. Ann. Med. 27:359-367, 1995
PubMed
P.87 掲載の参考文献
1) 今宿晋作:血球貪食症候群 (Hemophagocytic syndrome:HPS). 日小血会誌5:349-360, 1991
 
2) Wong, K.F. et al.:Hemophagocytic disorders-A review. Hematol. Rev. 5:5-37, 1991
 
3) Favara, B.E.:Hemophagocytic lymphohistiocytosis:a hemophagocytic syndrome Semin. Diagn. Pathol. 9:63-74, 1992
PubMed
4) 今宿晋作:血球貪食症候群とは. 血液・腫瘍科33:433-439, 1996
 
P.91 掲載の参考文献
1) 和久敬蔵, 井上圭三編:血小板活性化因子. 東京化学同人, 東京, 1989
 
2) Izumi, T. and Shimizu, T.:Platelet-activating factor:gene expression and signal transduction Biochim. Biophys. Acta 1259:317-333, 1995
PubMed
3) Snyder, F.:Platelet-activating factor:the biosynthetic and catabolic enzymes. Biochem. J. 305:689-705, 1995
PubMed
P.93 掲載の参考文献
1) Claesson-Welsh, L.:Platelet-derived growth factor receptor signals. J. Biol. Chem. 269:32023-32026, 1994
PubMed
2) Heldin, C.H. and Westermark, B.:Platelet-derived growth factor (PDGF). In:Guidebook to Cytokines and their Receptors. ed. by Nicola, N., Oxford University Press, Oxford, 1994, pp. 202-204
 
3) 横手幸太郎:PDGFによるシグナル伝達. 実験医学増刊 15:35-41, 1997
 
P.95 掲載の参考文献
1) Rose, M.:The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Rev. 7:94-98, 1993
PubMed
2) Shumak, K.H., Rock, G.A. and Nair, R.C.:Late relapse in patients successfully treated for thrombotic thrombocytopenic purpura. Ann. Intern. Med. 122:569,-573 1995
 
3) Thompson, C.E.:Thrombotic microangiopathies in the 1980s:clinical features, respose to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 80:1890-1898, 1992
 
P.97 掲載の参考文献
1) Barnes, S. and Peterson, T.G.:Biochemical targets of the isoflavone genistein in tumor cell lines. Proc. Soc. Exp. Biol. Med. 208:103-108, 1995
PubMed
2) Constantinou, A. and Huberman, E.:Genistein as an inducer of tumor cell differentiation:possible mechanisms of action. Proc. Soc. Exp. Biol. Med. 208:109-115, 1995
PubMed
3) 上原至雅:チロシンキナーゼ阻害剤. 実験医学15:236-241, 1993
 
P.99 掲載の参考文献
1) Weller, P.F. and Bubley, G.J.:The idiopathic hypereosinophilic syndrome. Blood 83:2759-2779, 1994
PubMed
2) Flaum, M.A., Schooley, R.T., Fauci, A.S. et al.:A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestation. Blood 58:1012-1020, 1981
PubMed
3) 榎原英夫, 小池利幸:好酸球の増加する疾患と治療. 日常診断と治療6:37-45, 1996
 
P.101 掲載の参考文献
1) Coller, B.S.:GP II b/III a inhibitor. Thromb. Heamost. 26:285, 1997
 
2) 池田康夫:GPIIb/IIIaインヒビター. 血栓と循環6:76-83, 1998
 
P.103 掲載の参考文献
1) 武谷浩之:抗リン脂質抗体の作用機序. Mebio 8:31, 1997
 
P.105 掲載の参考文献
1) 日本骨髄バンク (JMDP) コーディネートマニュアル, 7改訂, 骨髄移植推進財団, 1994, p. 5
 
2) 日本骨髄バンクニュース, vol. 11, 1997, p. 9
 

さ行 再生不良性貧血とHLA

P.107 掲載の参考文献
1) Nakao, S., Takamatsu, H., Yamaguchi, M. et al.:Identification of a specific HLA class II haplotype strongly associated with susceptibiliity to cyclosporine-dependent aplastic anemia. Blood 84:4257-4261, 1994
 
2) 中尾真二:再生不良性貧血におけるHLAクラスII遺伝子. Annual Review 血液1995, 高久史麿ほか編, 中外医学社, 東京, 1995, pp.55-61
 
P.109 掲載の参考文献
1) Fonseca, R. and Tefferi, A.:Practical aspects in the diagnosis and management of aplastic anemia. [184 refs]. Am. J. Med. Sci. 313:159-169, 1997
 
2) Young, N.S. and Maciejewski, J.:The pathophysiology of acquired aplastic anemia. [Review][72 refs]. N. Engl. J. Med. 336:1365-1372, 1997
 
3) Paquette, R.L:Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin:comparison with bone marrow transplantation. Blood 85:283-290, 1995
PubMed
P.111 掲載の参考文献
1) Wagner, J., Kernan, N.A., Steinbuch, M. et al.:Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 346:215-219, 1995
 
2) Kurtzberg, J., Laughlin, M., Graham, M.L. et al.:Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med. 335:157-166, 1996
PubMed
P.115 掲載の参考文献
1) Watanabe, S. and Arai, K.:Roles of the JAK-STAT system in signal transduction via cytokine receptors. Curr. Opin. Genet. Dev. 6:587-596, 1996
PubMed
2) Darnell, J.E. Jr.:STATs and gene reguration. Science 277:1630-1635, 1997
 
3) Horvath, C.M. and Darnell, J.E. Jr.:The state of the STATs:recent developments in the study of signal transduction to the nucleus. Curr. Opin. Cell Biol. 9:233-239, 1997
 
P.117 掲載の参考文献
1) Williams, C.S. and DuBois, R.N.:Prostaglandin endoperoxide synthase:why two isoforms? Am. J. Physiol. 270:G393-G400, 1996
PubMed
2) Griswold, D.E. and Adams, J.L.:Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2):rationale for selective inhibition and progress to date. Med. Res. Rev. 16:181-206, 1996
 
3) 森田育男:COXの発現調節とその異常. NOSとCOX-遺伝子から臨床へ, 平田結喜緒, 森田育男編, メディカルレビュー社, 東京, 1996, pp.109-193
 
P.119 掲載の参考文献
1) Civin, C.I., Strauss, L.C., Brovall, C. et al.:Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J. Immunol. 133:157-165, 1984
 
2) Krause, D.S., Fackler, M.J., Civin, C.I. et al.:CD34:structure, biology, and clinical utility. Blood 87:1-13, 1996
PubMed
3) 久米晃啓, 多田淳一, 須田年生:CD34の構造. 機能および臨床応用, Annual Review 血液1997, 高久史麿ほか編, 中外医学社, 東京, 1997, pp.10-17
 
P.121 掲載の参考文献
1) Emanuel, P.D., Bates, L.J., Castleberry, R.P. et al.:Selective hypersensitivity to granulocyte-macrophage colony-stimulationg factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77:925-929, 1991
 
2) Sawai, N., Koike, K., Ito, S. et al.:Aberrant growth of granulocyte-macrophage progenitors in juvenile chronic myelogenous leukemia in serum-free culture. Exp. Hematol 24:116-122, 1996
PubMed
3) Bollag, G., Clapp, D.W., Shih, S. et al.:Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12:144-148, 1996
PubMed
4) Largaespada, D.A., Brannan, C.I., Jenkins, N.A. et al.:NF1 deficiency causes Ras mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nat. Genet. 12:137-143, 1996
PubMed
5) Miyauchi, J., Asada, M., Sasaki, M. et al.:Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 83:2248-2254, 1994
 
6) Iverson, P.O., Rodwell, R.L., Pitcher, L. et al.:Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulation factor analogue E21R. Blood 88:2634-2639, 1996
 
P.123 掲載の参考文献
1) Meydan, N., Grunberger, T., Dadi, H. et al.:Inhibition of acute lymphoblastic leukemia by Jak-2 inhibitor. Nature 379:645-648, 1996
PubMed
2) Ihle, J.N., Witthuhn, BA, Quelle, F.W. et al.:Signaling through the hematopoietic cytokine receptors. Ann. Rev. Immunol. 13:369-398, 1995
 
3) 湯尾明:シグナル伝達阻害剤による白血病の治療. Annual Review 血液1997, 高久史麿ほか編, 中外医学社, 東京, 1997, pp.97-106
 
P.125 掲載の参考文献
1) Felder, J.N., Gnirke, W., Thomas, Z. et al.:A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13:399-407, 1996
 
2) Hershko, C., Pinson, A. and Link, G.:Prevention of anthracyclin cardiotoxicity by iron chelation. Acta Haematol. 95:87-92, 1996
PubMed
3) Olivieri, N.F., Brittenham, G.M., Matsui, D. et al.:Iron chelation therapy with oral deferiprone in patients with thalassemia major. N. Engl. J. Med. 91:918-922, 1995
 
P.127 掲載の参考文献
1) Ikeda, Y. et al.:von Willebrand factor dependent shear-induced platelet aggregation.:basic mechanisms and clinical implications. Ann. NY Acad. Sci. 811:325, 1997
PubMed
2) Ruggeri, Z.:Mechanisms of shear-induced platelet adhesion and aggregation. Thromb. Haemost. 70:119, 1993
PubMed
P.129 掲載の参考文献
1) Shimoyama, M. and members of The Lymphoma Study Group:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br. J. Haematol. 79:428-437, 1991
 
P.131 掲載の参考文献
1) Old, J.:Haemoglobinopathies. Prenat. Diagn. 16:1181-1186, 1996
PubMed
2) Miwa, S. and Fujii, H.:Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia:tabulation of mutant enzymes. Am. J. Hematol. 51:122-132, 1996
 
3) Delaunay, J.:Genetic disorders of red cell membranes. FEBS Lett. 369:34-37, 1995
PubMed
P.133 掲載の参考文献
1) Kitchens, C.S.:Thrombophilia and thrombosis in unusual sites. In:Hemostasis and Thrombosis:basic principles and clinical practice, third edition, ed. by Colman, R.W., Marder, V.J. et al., Lippincott Company, Philadelphia, 1994, pp.1255-1273
 
2) Hirsh, J., Prins, M.H. and Samama, M.:Approach to the thrombophilic patients for hemostasis and thrombosis:basic principles and clinical practice. In:Hemostasis and Thrombosis:basic principles and clinical practice, third Edition, ed. by Colman, R.W., Hirsh, J., Marde, V.J. et al., Lippincott Company, Philadelphia, 1994, pp.1543-1561
 
P.135 掲載の参考文献
1) Miyajima, A., Kitamura, T., Harada, N. et al.:Cytokine receptors and signal transduction. Annu. Rev. Immunol. 10:295-331, 1992
PubMed
2) O'Shea, J.J.:Jaks, STATs, cytokine signal transduction, and immunoregulation:are we there yet?Immunity 7:1-11, 1997
PubMed
P.137 掲載の参考文献
1) Ogawa, M.:Differentiation and proloferation of hematopoietic stem cells. Blood 81:2844-2853, 1993
 
2) 大沢匡毅, 中内啓光:造血幹細胞の自己複製と多分化能. Annual Review 免疫1997, 菊池浩吉, 奥村康, 矢田純一編, 中外医学社, 東京, 1996, pp.1-12
 
3) Morrison, S.J., Shah, N.M. and Anderson, D.J.:Regulatory mechanisms in stem cell biology. Cell 88:287-298, 1997
PubMed
P.139 掲載の参考文献
1) Nakahata, T., Sui, X., Tajima, S. et al.:Ex vivo expansion of human primitive hemopoietic progenitors. In:Bone Marrow Trans-Plantation-Basic and Clinical Studies, ed. by Ikehara, S., Takaku, F. and Good, R.A., Springer-Verlag, Tokyo, 1996, pp.47-63
 
2) 辻浩一郎:幹細胞のin vitro増幅, 臨床血液37:579-583, 1996
 
3) Emerson, S.G.:Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells:the next generation of cellular therapeutics. Blood 87:3082-3088, 1996
PubMed
P.141 掲載の参考文献
1) Nemerson, Y.:Tissue factor:then and now. Thromb. Haemost. 74:180-184, 1995
PubMed
2) Mackman, N.:Regulation of tissue factor gene. FASEB J. 9:883-889, 1995
PubMed
3) 中村伸:単球での組織因子発現とその生体内機能. 血液・腫瘍科33:273-283, 1996
 

た行 耐性克服薬

P.143 掲載の参考文献
1) Raderer, M. and Scheithauer, W.:Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553-3563, 1993
PubMed
2) Lum, B.L., Fisher, G.A., Brophy, N.A. et al.:Clinical trials of modulation of multidrug resistance:pharmacokinetic and pharmacodynamic considerations. Cancer 72:3502-3514, 1993
PubMed
3) List, A.F.:Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10:937-942, 1996
PubMed
P.145 掲載の参考文献
1) 戸川敦:多発性骨髄腫と類縁疾患, 専門医のための血液学レビュー'97, 小峰光博, 斉藤英彦, 溝口秀昭監修, 総合医学社, 東京, 1997, pp. 175-179
 
2) Greipp, P.R.:Advances in the diagnosis and management of myeloma. Semin. Hematol. 29 (suppl. 2):24-45, 1992
 
3) Alexanian, R. and Dimopoulos, M.A.:Management of multiple myeloma. Semin. Hematol. 32:20-30, 1995
PubMed
P.147 掲載の参考文献
1) Appelbaum, T.R., Le Beau, M.M. and William, C.L.:Hematology 1996 education program American Society of Hematology ASH, Washington DC, 1996, pp.33-47
 
2) Smith, M.A., McCaffrey, R.P. and Karp, J.E.:The secondary leukemias. Challenges and research directions. J. Natl. Cancer Inst. 88:407-418, 1996
PubMed
3) 竹山邦彦, 上田龍三:治癒関連白血病/MDSの特徴と成因. 医学のあゆみ175:878-881, 1995
 
P.149 掲載の参考文献
1) Casu, B.:Structure and biological activity of heparin. Adv. Carbohydr. Chem. Biochem. 43:51-134, 1985
PubMed
2) Fareed, J., Hoppensteadt, D.A. and Walenga, J.M.:Current perspectives on low molecular weight heparins. Semin. Thromb. Hemostas. 19 (suppl.1):1-11, 1993
 
3) Hirsh, J. and Levine, M.N.:Low molecular weight heparin. Blood 79:1-77, 1992
PubMed
P.151 掲載の参考文献
1) Aoki, Y., Muranaka, S., Nakabayashi, K. et al.:δ-aminolevulinic acid synthetase in erythroblasts of patients with pyridoxine-responsive anemia. J. Clin. Invest. 64:1196-1203, 1979
 
2) Cotter, P.D., Baumann, M. and Bishop, D.:Enzymatic defect in X-linked sideroblastic anemia:molecular evidence for erythroid δ-aminolevulinate synthase deficiency. Proc. Natl. Acad. Sci. USA 89:4025-4032, 1992
 
3) Cox, T.C., Bottomley, S.S., Willey, J.S. et al.:X-linked pyridoxine-responsive sideroblastic anemia due to a Thr 388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N. Engl. J. Med. 330:675-679, 1994
 
P.153 掲載の参考文献
1) Brito-Babapulle, F. et al:Clinical and laboratory features of de novo acute myeloid leukemia with trilineage myelodysplasia. Br. J. Haematol. 66:445-450, 1987
PubMed
2) Kuriyama, K. et al.:Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia. Br. J. Haematol. 86:767-773, 1994
PubMed
P.155 掲載の参考文献
1) Kim, N.W., Piatyszek, M.A., Prowse, K.R. et al.:Specific association of human telomerase activity with immortal cells and cancer. Science 236:2011-2015, 1994
 
2) Tatematsu, K., Nakayama, J., Danbara, M. et al.:A novel quantitative "stretch PCR assay" that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene 13:2265-2274, 1996
PubMed
3) Harley, C.B. and Villeponteau, B.:Telomeres and telomerase in aging and cancer. Curr. Opin. Genet. Dev. 5:249-255, 1995
PubMed
4) Ishikawa, F.:Telomere crisis, the driving force in cancer cell evolution. Biochem. Biophys. Res. Commun. 230:1-6, 1997
PubMed
5) Nakayama, J., Tahara, H., Tahara, E. et al.:Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet. 18:65-68, 1998
PubMed
P.159 掲載の参考文献
1) Derynck, R.:Transforming growth factor-beta. In:The Cytokine Handbook. 2nd Ed., ed. by Thomson, A, Academic Press, San Diego, CA, 1994, pp. 319-342
 
2) Massague, J.:TGFβ signaling:receptors, transducers, and Mad proteins. Cell 85:947-950, 1996
 
3) 山下英俊, 宮園浩平:TGF-βスーパーファミリーの分子生物学, 実験医学バイオサイエンスシリーズ17, 羊土社, 東京, 1994
 
4) 羽田明子:TGF-βファミリーのシグナル伝達系におけるSmad の役割. 実験医学15:2092-2095, 1997
 
5) 川畑正博, 宮園浩平:Smad:TGF-βスーパーファミリーの新規シグナル伝達分子 (特集) 実験医学16:854-895, 1998
 
P.161 掲載の参考文献
1) Kasai M., Matsuzaki, T., Katayanagi, K. et al.:The Translin ring specifically recognizes DNA ends at recombination hotspots in the human genome. J. Biol. Chem. 272:11402-11407, 1997
 
2) Aoki, K., Suzuki, K., Sugano, T. et al.:A novel gene, Translin, encodes a recombination hotspot binding protein associated with chromosomal translocations in human lymphoid neoplasms. Nat. Genet. 10:167-174, 1995
PubMed
3) Aoki, K., Nakahara, K., Ikegawa, C. et al.:Nuclear proteins binding to a novel target sequence within the recombination hotspot regions of Bcl-2 and the immunoglobulin DH gene family. Oncogene 9:1109-1115, 1994
PubMed
4) Kasai, M., Maziarz, R.T., Aoki, K. et al.:Molecular involvement of the pvt-1 locus in a γ/δT-cell leukemia bearing a variant t(8;14)(q24;q11) translocation. Mol. Cell. Biol. 12:4751-4757, 1992
 
5) Maziarz, R.T., Arceci, R.J., Bemstein, S.C. et al.:A γ/δ+T cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer activity. Blood 79:1523-1531, 1992
 
P.163 掲載の参考文献
1) Vu, T.-K., Huang, D.T., Wheaton, V.I. et al.:Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanisms of a receptor activation. Cell 64:1057-1068, 1991
 
2) Maruyama, Y., Maruyama, I. and Soejima, Y.:Thrombin receptor agonist peptide decreases thrombomodulin activity in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 199:1262-1269, 1994
PubMed
3) Shin, H.:Thrombin receptor-mediated synovial proliferation in patients with rhematoid arthritis. Clin. Immunol. Immunopathol. 76:225-233, 1996
 
4) Nakajima, T., Kitajima, I., Shin, H. et al.:Involvement of NF-κB activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem. Biophys. Res. Commun. 204:950-958, 1994
 
5) Molino, M., Barnathan, E.S., Numerof, R. et al.:Interactions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. 272:4043-4049, 1997
PubMed
6) Ishihara, H., Connolly, A., Zeng, D. et al.:Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502-506
 
P.165 掲載の参考文献
1) 平田雅一, 林康紀, 成宮周:トロンボキサン受容体のcDNAクローニング. 実験医学 9:1485-1489, 1991
 
2) Negishi, M., Sugimoto, Y. and Ichikawa, A.:Molecular mechanisms of diverse actions of prostanoid receptors. Biochem. Biophys. Acta. 1259:220-223, 1995
 
3) 牛首文隆, 平田雅一, 成宮周ほか:プロスタグランジン受容体. 現代医療 27:1873-1886, 1995
 
4) Hirata, T., Ushikubi, F, Narumiya, S. et al.:Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J. Clin. Invest. 97:949-956, 1996
PubMed
P.167 掲載の参考文献
1) Kaushansky, K.:Thrombopoietin:the primary regulator of platelet production. Blood 86:419, 1995
PubMed
2) 溝口秀昭:トロンボポエチン. 最新内科学体系, プログレス3, 血液・造血器疾患 (押味和夫編), 中山書店, 東京, p.294
 
P.169 掲載の参考文献
1) Ishii, H.:The detection and measurement of thrombomodulin. In:Thrombin, thrombomodulin and the control of hemostasis. ed. by Giddings, J.C., R.G. Landes Company, Austin, 1994, pp. 12-141
 
2) 石井秀美:トロンボモジュリンの抗凝固活性と発現の調節. 生化学67:307-312, 1995
 
3) 石井秀美:血管内皮細胞傷害マーカーとしてのトロンボモジュリン. 血液・腫瘍科28:248-256, 1994
 

な行 Nuclear factor erythroid 2

P.171 掲載の参考文献
1) Shivdasani, R.A., Rosenblatt, M.F., Orkin, S.H. et al.:Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81:695-704, 1995
PubMed
2) Andrews, N.C., Bromage, H.E., Orkin, S.H. et al.:Erythroid transcription factor NF-E2 is ahematopoietic-specific basic-leusine zipper protein. Nature. 363:722-728, 1993
 
3) Kotkow, K.J. and Orkin, S.H.:Complexity of the erythroid transcription factor NF-E2 as revealed by gene targeting of the mouse p18 NF-E2 locus. Proc. Natl. Acad. Sci. USA 93:3514-3518, 1996
PubMed
4) Shivdasani, R.A., Fujiwara, Y., Orkin, S.H. et al.:A lineage-selsective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 16:3965-3973, 1997
PubMed
P.173 掲載の参考文献
1) Petio, C.K., Gottlieb, G.J., Dougherty, J.H. et al.:Neoplastic angioendotheliosis:ultrastructural study and review of the literature. Ann. Neurol. 3:393-399, 1978
 
2) Mori, S., Itoyama S., Mohri. N. et al.:Cellular characteristics of neoplastic angioendotheliosis:an immunohistological marker study 6 cases. Virchows Arch. A Pathol. Anat. Histopathol. 407:167-175, 1985
PubMed
3) Mock, D.J., Jundt, J.W., Green, J.B. et al.:Angiotropic lymphoma manifested by fever and painful swollen legs. South. Med. J. 86:1432-1435, 1993
PubMed

は行 白血病抑制因子

P.175 掲載の参考文献
1) Alexander, H.R., Billingsley, K.G., Block, M.I. et al.:D-factor/leukemia inhibitory factor:evidence for its role as a mediator in acute and chronic inflammatory disease. Cytokine 6:589-596, 1994
PubMed
2) Taga, T.:gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J. Neurochem. 67:1-10, 1966
 
3) 前川平, 阿部達生:分化誘導促進因子D因子/LIFの生物活性. 造血因子3:222-231, 1992
 
4) 冨田幹夫:LIF/D因子の細胞膜レセプターと可溶性レセプター. 医学のあゆみ174:1109-1113, 1995
 
P.177 掲載の参考文献
1) Bick, R.L.:Disseminated intravascular coagulation:objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin. Appl. Thromb/Hemostas 1:3-23, 1995
 
2) 松田保:DICの臨床. 新興医学出版, 東京, 1997, pp.1-141
 
P.179 掲載の参考文献
1) 三木徹:3q27転座型悪性リンパ腫, 白血病とリンパ腫の分子生物学, 平井久丸編, 中外医学社, 東京, 1995, pp.97-103
 
2) Onizuka, T., Moriyama, M., Yamochi, T. et al.:BCL-6 gene product, a 92-to 98-kDa nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. Blood 86:28-37, 1995
 
3) Chang, C.C., Ye, B.H., Chaganti, R.S. et al.:BCL6, a POZ / zinc-finger protein, is a sequence-specific transcriptional repressor. proc. Natl. Acad. Sci. USA 93:6947-6952, 1996
PubMed
P.181 掲載の参考文献
1) Parker, C.J.:Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells 14:396-411, 1996
PubMed
2) Rosse, W.F.:Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 76:63-93, 1997
PubMed
3) 木谷照夫:PIG-A 遺伝子と発作性夜間血色素尿症 Annual Review 血液1997, 高久史麿ほか編, 中外医学社, 東京, 1997, pp. 59-72
 
P.183 掲載の参考文献
1) Hirama, T. and Koeffler, H.:Role of the cyclin-depndent kinase inhibitors in the development of cancer. Blood 86:841-854, 1995
 
2) 小川誠司:p15, p16遺伝子と白血病:Annual Review 血液 1996, 高久史麿中外医学社, 東京, 1996, pp.106-122
 
P.185 掲載の参考文献
1) 半田誠:P-セレクチン. 臨床血液 36:638, 1995
 
P.187 掲載の参考文献
1) Travis, W.D. and C.Y.:Mast cell desease. In:The Mast Cell in Health and Disease. ed. by Kaliner, M.A. and Metcalfe, D.D., Marcel Dekker, New York, 1993, pp.723-741
 
2) Kitamura, Y.:Regulation mechanisms of development, servival and malignant transformation of mast cells. Asian Med. J. 39:210-216, 1996
 
3) Tsujimura, T., Kanakura, Y. and Kitamura, Y.:Mechanisms of constitutive activation of c-kit receptor tyrosine kinase. Leuk. Res. 11 (supple. 3):396-398, 1997
 
P.189 掲載の参考文献
1) Ferry, J.A., Sklar, J., Zukerberg, L.R. et al.:Nasal lymphomas:aclinicophathologic study with immunophenotypic and genotypic analysis. Am. J. Surg. Pathol. 15:268-279, 1991
PubMed
2) Suzumiya, J., Takeshita, M., Kimura, N. et al.:Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 83:2255-2260, 1994
PubMed
3) Jaffe, E.S., Chan, J.K., Su, I.J. et al.:Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am. J. Surg. Pathol. 20:103-111, 1996
PubMed
P.191 掲載の参考文献
1) Markwardt, F.:The comeback of hirudin-an old-established anticoagulant agent. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. 115:10-23, 1998
 
2) Stringer, K.A. and Lindenfeld, J.:Hirudins:antithrombin anticoagulants. Ann. Pharmacother 26:1535-1540, 1992
PubMed
P.193 掲載の参考文献
1) Butturini, A., Gale, R.P., Verlander, P.C. et al.:Hematologic abnormalitis in Fanconi anemia:an International Fanconi Anemia Registry study. Blood 84:1650-1655, 1994
 
2) Gluckman, E., Auerbach, A.D., Horowitz, M.M. et al.:Bone marrow transplantation for Fanconi anemia. Blood 86:2856-2862, 1995
PubMed
P.195 掲載の参考文献
1) Fujimura, Y. and Titani, K.:Structure and function of von Willebrand factor. In:Haemostasis and Thrombosis, ed. by Bloom, A.L., Forbes, C.D., Thomas, D.P. et al., Churchill-Livingstone, 1993. pp. 379-395
 
P.197 掲載の参考文献
1) Bachmann, T.:The plasminogen-plasmin enzyme system in. Hemostasis and Thrombosis 3rd Edition, ed. by Colman, R., Hirsh, J., Marder, V. et al. Lippincott Comp, Philadelphia, 1994, pp. 1592-1622
 
2) 一瀬白帝:線溶系異常症. 図説・分子病態学, 一瀬白帝, 鈴木宏治編, 中外医学社, 東京, 1995, pp. 283-288
 
3) Gulba, D.D., Bode, C., Runge, M.S. et al.:Thrombolytic agents-an overview. Ann. Hemotol. 73:S9-S27, 1996
 
P.199 掲載の参考文献
1) 窓岩清治, 坂田洋一:血管内皮プラスミノゲンアクチベータインヒビターと血栓症血管と内皮6:54-60, 1996
 
2) 三室淳:プラスミノゲンアクチベータインヒビター, 止血・血栓・線溶, 松田道生, 鈴木宏治編, 中外医学社, 東京, 1994, pp. 267-274
 
P.201 掲載の参考文献
1) Tallman, M.S. and Hakimian, D.:Purine nucleoside analogs:Emerging roles in indolent lymphoproliferative disorders. Blood 86:2463-2474, 1995
PubMed
P.203 掲載の参考文献
1) Williams, C.S. and DuBois, R.N.:Prostaglandin endoperoxide synthase:why two isoforms? Am.J. Physiol. 270:G393-G400, 1996
PubMed
2) Griswold, D.E. and Adams, J.L.:Con:stitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2):rationale for selective inhibition and progress to date. Med. Res. Rev. 16:181-206, 1996
 
3) 森田育男:COXの発現調節とその異常. NOSとCOX-遺伝子から臨床へ, 平田結喜緒, 森田育男編, メディカルレビュー社, 東京, 1996, pp. 109-193
 
P.205 掲載の参考文献
1) Suzuki, K., Deyashiki, Y., Nishioka, J. et al.:Protein C inhibitor:structure and function. Thromb. Haemost. 61:337-342, 1989
PubMed
2) 林辰弥, 鈴木宏治:プロテインCインヒビター. Annual Review 血液1995, 中外医学社, 東京, 1995, pp. 308-315
 
3) Kise, H., Nishioka, J. and Suzuki, K.:Characterization of semenogelin II, and its molecular interaction with prostate specific antigen and protein C inhibitor. Eur. J. Biochem. 238:88-96, 1996
PubMed
P.207 掲載の参考文献
1) 高橋芳右:プロトロンビンフラグメントF1+2. 検査値のみかた, 中井利昭編, 中外医学社, 東京, 1996, pp. 485-486
 
2) Bruhn, H.D., Conard, J., Mannucci, M. et al.:Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination. Thromb. Haemost. 68:413-417, 1992
PubMed
3) 高橋芳右:凝固・線溶分子マーカー. 現代医療24:3161-3167, 1992
 
P.209 掲載の参考文献
1) 大野竜三:急性前骨髄球性白血病の治療-レチノイン酸による治療と問題点-. 医学のあゆみ175:976-979, 1995
 
2) 大野竜三:分化誘導療法の急性前骨髄球性白血病における有用性と他の悪性腫瘍への応用の可能性. 臨床成人病26:851-854, 1996
 
3) 大野竜三:急性前骨髄球性白血病におけるall-trans retinoic acid療法の現状と今後の方向. 臨床血液37:760-765, 1996
 
P.211 掲載の参考文献
1) 待井隆志:ヘアリー細胞白血病のIFN療法. カレントテラピー13:121-126, 1995
 
2) Jaiyesimi, I.A. et al.:Advances in therapy for hairy cell leukemia. A review. Cancer 72:5-16, 1993
PubMed
3) Delannoy, A.:2-chlolo-2'-deoxyadenosine:clinical applications in hematology. Blood Rev. 10:148-166, 1996
 
P.213 掲載の参考文献
1) Chong, B.H.:Heparin-induced thrombo cytopenia. Br. J. Haematol. 89:431-439, 1995
 
2) Schmidt, B.P. and Adelman, B.:Heparin-associated thrombocytopenia:a critical view and a pooled analysis. Am. J. Med. Sci. 305:208-215, 1993
 
3) Warkentin, T.E., Levine, M.N., Hirsh, J. et al.:Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N. Engl. J. Med. 332:1330-1335, 1995
PubMed
P.215 掲載の参考文献
1) 寺尾俊彦, 中島彰, 金山尚格ほか:HELLP症候群. 産婦人科の実際 41:1373-1379, 1992
 
2) 寺尾俊彦:血管攣縮, 血液凝固と妊娠・分娩:HELLP 症候群. 臨床婦人科産科 49:594-596, 1995
 
P.217 掲載の参考文献
1) Fisher, S.K.:Homologous and heterologous regulation of receptorstumulated phosphoinositide hydrolysis. Eur. J. Pharmacol. 288:231-250, 1995
PubMed
2) Powis, G. and Phil, D.:Inhibitor of phosphatidylinositol signaling as antiproliferative agents. Cancer Metastasis Rev. 13:91-130, 1994
PubMed
3) 竹縄忠臣:脂質研究の新展開シグナリングにおける新しい機能. 実験医学増刊 14:86-104, 1996
 
P.219 掲載の参考文献
1) In:Guidebook to the Homeobox Genes, ed. by. Duboule, D., Oxford University Press, New York, 1994
 
2) Lawrence, P.A. and Morata, G.:Homeobox genes:their function in drosophila segmentation and pattern formation. Cell 78:181-189, 1994
PubMed
3) Lawrence, H.J., Sauvageau, G., Humphries, R.K. et al.:The role of HOX homeobox genes in normal and leukemic hematopoiesis. Stem Cells 14:281-291, 1996
PubMed

ま行 マクロファージコロニー刺激因子

P.221 掲載の参考文献
1) Motoyoshi, K:Macrophage colony-stimulating factor for cancer therapy. Oncology 51:198-204, 1994
PubMed
2) 元吉和夫:M-CSFと疾患. 最新医学71:1777-1782, 1996
 
3) 元吉和夫:M-CSFの臨床応用. 診断と治療84:491-495, 1996
 
4) Motoyoshi, K.:Biological activities and clinical application of M-CSF. Int. J. Hematol. 67:109-122, 1998
PubMed
P.223 掲載の参考文献
1) 原田実根, 薗田精一, 高上洋一 (編):末梢血幹細胞移植-基礎から臨床まで-. 南江堂, 東京, 1995
 
2) 原田実根:同種末梢血幹細胞移植. 癌と化学療法23:1877-1885, 1996
 
3) Champlin, R.E.:Peripheral blood progenitor cells:a replacement for marrow transplantation? Semin. Oncol. 23 (Suppl. 4):15-21, 1996
 
P.225 掲載の参考文献
1) Isaacson, P.G. and Wright, D.H.:Malignant lymphoma of mucosa-associated lymphoid tissue:a distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1983
 
2) Wotherspoon, A.C., Oritz-Hidalgo, C., Falzon, M.R. et al.:Helicobacter pylori-associated gas tritis and primary B-cell gastric lymphoma. Lancet 338:1175-1176, 1991
 
3) 斉藤大三:胃原発性悪性リンパ腫. 日常診療と血液6:911-915, 1996
 
4) Ilver, D. et al.:Helicobacter pylori:adhesion binding fucosylated histo-blood group antigens revealed by retagging. Science 279:373-377, 1998
PubMed
P.227 掲載の参考文献
1) Kantarjian, H.M., O'Brien, S., Anderlini, P. et al.:Treatment of chronic myelogenous leukemia:current status and investigational options. Blood 87:3069-3081, 1996
PubMed
P.229 掲載の参考文献
1) Raffeld, M. and Jaffe, E.S.:bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 78:259-263, 1991
PubMed
2) Motokura, T. and Arnold, A.:Cyclins and oncogenesis. Biochim. Biophys. Acta 1155:63-78, 1993
PubMed
3) Weisenburger, D.D. and Armitage, J.O.:Mantle cell lymphoma-an entity comes of age. Blood 87:4483-4494, 1996
PubMed
P.231 掲載の参考文献
1) Kadin, M.E.:Ki-1/CD30+(canaplastic) large cell lymphoma:maturation to a clinico-pathologic entity with prospects of effective therapy [Editorial]. J. Clin. Oncol. 12:884-887, 1994
 
2) Shiota, M., Nakamura, S., lchinohasama, R. et al.:Anaplastic large cell lymphomas expressing the novel chimeric protein p80MPM:ALK:a distinct clinicopathologic entity. Blood 86:1594-1560, 1995
 
3) Foss, H.-D., Anagnostopoulos, I., Araujo, I. et al.:Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88:4005-4011, 1996
PubMed
P.233 掲載の参考文献
1) Courty, J., Courtois, Y. and Barritault, D.:In vitro properties of various growth factors and in vivo effects. Biochimie 66:419-428, 1984
PubMed
2) Albert, P., Boilly, B. and Courty, J.:Stimulation in cell culture of mesenchymal cells of newt limb blastemas by EDGF I or II (basic FGF or acidic FGF). Cell Differ. 21:63-68, 1987
 
3) Bisilico, C. and Moscatelli, D.:The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59:115-165, 1992
 
P.235 掲載の参考文献
1) Luna-Fineman, S., Shannon, K.M. and Lange, B.J.:Childhood monosomy 7:epidemiology, biology, and mechanistic implications. Blood 85:1985-1999, 1995
 
2) Baranger, L, Baruchel, A., Leverger, G. et al.:Monosomy-7 in childhood hemopoietic disorders. Leukemia 4:345-349, 1990
PubMed

や行 輸血後移植片対宿主病

P.237 掲載の参考文献
1) 日本輸血学会輸血後GVHD対策小委員会:日本輸血学会会告-輸血によるGVHD予防のための血液に対する放射線照射ガイドラインIII. 日本輸血学会雑誌 42:1-9, 1996
 
2) 井野隆史, 松浦昭雄, 高梨梨一郎ほか:手術時の輸血によるGVHD様症候群. 外科48:706-712, 1986-1987
 
3) 羽藤高明, 安川正貴:OKT3とサイクロスポリンAの投与によって救命し得た輸血後GVHD症例. 日本輸血学会雑誌40:539-541, 1994
 
4) Nishimura, M., Akaza, T., Tadokoro, K. and Juji, T.:Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion-associated graft-versus-host disease. Transfusion 37:768-770, 1997
PubMed
5) Yahagi, H., Uchida, S., Takahashi, M. et al.:Recovery of patient peripheral blood mononuclear cells after treatment with protease inhibitor in post-transfusion graft-versus-host disease. Proc. Jpn. Academy 73 (B) No. 5:79-84, 1997
 

ら行 ラミニン

P.239 掲載の参考文献
1) Beck, K., Hunter, I. and Engel, J.:Structure and function of laminin:anatomy of a multidomain glycoprotein. FASEB J. 4:148-160, 1990
PubMed
2) Timpl, R. and Brown, J.C.:The Laminins. Matrix Biol. 14:275-281, 1994
 
3) Mercurio, A.M.:Laminin receptors:achieving specificity through cooperation. Trends Cell Biol. 5:419-423, 1995
PubMed
P.241 掲載の参考文献
1) Kanemaru, A., Takemoto, Y., Tanimoto, M. et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202-1206, 1995
 
2) Frankel, S.R., Ardley, A., Lauwers, G. et al.:The "retinoic acid syndrome"in acute promyelocytic leukemia. Ann. Intern. Med. 117:292-296, 1992
 
3) Vahdat, L, Maslak, P., Miller, W.H. et al:Early motality and the retinoic acid syndrome in acute promyelocytic leukemia:impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isofom, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843-3849, 1994
 

書評

最近チェックした商品履歴

Loading...